Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NLA101 in AML with CIN
NCT03301597Phase 2Terminated
- Sponsor
- Nohla Therapeutics
- Start
- Jan 2018
- Primary completion
- Mar 2019
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Hematopoietic Stem Cells
- Countries
- 3
01
Overview
A Phase 2 trial of dilanubicel in chemotherapy-induced neutropenia (CIN), sponsored by Nohla Therapeutics. Started Jan 2018; status: terminated.
02
Drugs
dilanubicel
03
Conditions
chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on NCT03301597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03301597.